Results from US Government-Sponsored Phase 1 Trial of VSV Vaccine Reported
?An early-stage clinical trial of an experimental Ebola vaccine conducted at the National Institutes of Health (NIH) and the Walter Reed Army Institute of Research (WRAIR) found that the vaccine, called VSV-ZEBOV, was safe and elicited robust antibody responses in all 40 of the healthy adults who received it. The most common side effects were injection site pain and transient fever that appeared and resolved within 12 to 36 hours after vaccination. A report describing preliminary results of the NIH-WRAIR study appears online today in The New England Journal of Medicine. The VSV-ZEBOV candidate is one of two experimental Ebola vaccines now being tested in the phase 2/3 PREVAIL clinical trial that is enrolling volunteers in Liberia.
“The ongoing Ebola outbreak in West Africa is unprecedented in scope and duration,” said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. “The outbreak is slowly coming under control, thanks to extraordinary and multi-faceted efforts in the affected nations. However, there still are no licensed specific therapies or vaccines for Ebola. Until a safe and effective vaccine is available, the world will continue to be under-prepared for the next Ebola outbreak.”
Scientists at the Public Health Agency of Canada developed the candidate vaccine. It was licensed to NewLink Genetics Corp. of Ames, Iowa, a company collaborating with Merck & Co. Inc., of Kenilworth, New Jersey, which is responsible for advancing this vaccine towards regulatory approval. The investigational vaccine is based on a genetically modified and attenuated vesicular stomatitis virus (VSV), a virus that mainly affects cattle. In the investigational vaccine, a gene for a VSV protein is replaced with a gene segment from a key protein in the Zaire species of Ebola virus. The vaccine does not contain the whole Ebola virus and therefore cannot infect vaccinated persons with Ebola.
The new report summarizes results of the first 52 volunteers enrolled in the study: 26 at the NIH Clinical Center in Bethesda, Maryland, and 26 at the WRAIR clinic in Silver Spring, Maryland. Six volunteers at each site received a placebo injection of saline solution, and the remaining 40 received the experimental vaccine at either one of two different dosages (2 x107 or 3 x106 in 20 volunteers at each site). The NIH trial was led by NIAID investigators Richard T. Davey, Jr., M.D., and John H. Beigel, M.D., while Jason A. Regules, M.D., and Stephen J. Thomas, M.D., headed the trial at WRAIR.
The candidate vaccine’s ability to stimulate immune responses was assessed by sampling the volunteers’ blood at multiple time points following injection. (The blood sampling schedule differed between the two trial sites.) Of those volunteers tested at 14 days after injection, 93 percent (26 out of 28) of whose who had received vaccine developed antibodies against Zaire species of Ebola virus. Antibodies were detected in the remaining 14 volunteers who had received vaccine by 28 days after injection. Antibody responses were approximately three-fold greater in those who received the higher vaccine dose. This information was available to the designers of the PREVAIL trial and was used to guide the decision to use VSV-ZEBOV at the higher dosage level in that trial.
“The prompt, dose-dependent production of high levels of antibodies following a single injection and the overall favorable safety profile of this vaccine make VSV-ZEBOV a promising candidate that might be particularly useful in outbreak interventions,” said Dr. Davey.
The Latest on: Ebola Vaccine
via Google News
The Latest on: Ebola Vaccine
- Russia COVID-19 vaccine appears to lack crucial dataon August 12, 2020 at 2:06 pm
Does the Russian vaccine meet the American standard for testing? Mercer Island MD Dr. Gordon Cohen joined Seattle’s Morning News to discuss.
- Companies test antibody drugs to help treat and prevent coronavirus ahead of a vaccineon August 12, 2020 at 12:15 pm
It can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that ...
- Coronavirus: American vaccine produces ‘robust immune response’ in human trialson August 12, 2020 at 7:42 am
Antibodies against COVID-19 were present 21 days after a single vaccination, however some experienced side-effects including pain at the injection site, fatigue, headache, fever and sleep disturbance.
- Scientists uneasy as Russia approves 1st coronavirus vaccineon August 11, 2020 at 11:05 pm
Russia on Tuesday became the first country to approve a coronavirus vaccine, a move that was met with international skepticism and unease because the shots have only been studied in dozens of people.
- Scientists uneasy as Russia approves vaccineon August 11, 2020 at 10:17 pm
Russia on Tuesday became the first country to approve a coronavirus vaccine, a move that was met with international skepticism and unease because the shots have only been ...
- Covid-19 updates: Vaccine maker seeks to launch study; Gilead asks for remdesivir approvalon August 10, 2020 at 11:08 am
One company seeks formal FDA approval of its #Covid-fighting drug; another is asking the FDA to greenlight its experimental #coronavirus vaccine trial. $GILD $VXRT ...
- Russia's race for virus vaccine raises concerns in the Weston August 7, 2020 at 4:10 am
Russia boasts that it’s about to become the first country to approve a COVID-19 vaccine, with mass vaccinations planned as early as October using shots that are ...
- MNOV: Developing SARS-CoV-2 Vaccine Based on Parainfluenza Virus Vector…on August 4, 2020 at 12:20 pm
MNOV READ THE FULL MNOV RESEARCH REPORT Business Update Licenses SARS-CoV-2 Vaccine On July 27, 2020, MediciNova, Inc. (NASDAQ:MNOV) announced the company entered into a joint development agreement ...
- Merck ups outlook, turns profit during global vaccine hunton July 31, 2020 at 10:45 am
Surging sales of cancer medicines and reduced spending across the board helped Merck overcome a big hit from the coronavirus pandemic and pushed second quarter profits up by 12%.
- Ebola Vaccine Delay May Be Due To An Intellectual Property Disputeon July 28, 2020 at 5:01 pm
For the past six weeks, about 800 to 1,000 doses of an experimental ebola vaccine have been sitting in a Canadian laboratory instead of being dispensed to West Africa. The delay, it would now ...
via Bing News